Compass Therapeutics director Stephen Squinto resigns from board effective Aug 31

Compass Therapeutics, Inc.

Stephen Squinto, Ph.D., notified Compass of his resignation from the Board and all committees, effective August 31, 2022.
Resignation not due to any disagreement with the Company on operations, policies, or practices.
Dr. Squinto had been a Board member since 2015, representing an early investor; he is leaving to pursue other professional endeavors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stephen Squinto

Director

CMPX · Compass Therapeutics, Inc.

Effective: 2022-08-31
Filed: August 19, 2022, 7:59 PM ET

On August 17, 2022, Stephen Squinto, Ph.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective August 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Squinto resigned as Director at Compass Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On August 17, 2022, Stephen Squinto, Ph.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective August 31, 2022.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-005763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.